Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares

NEXT STORY
Ziopharm Oncology Announces Chief Financial Officer to Step Down
PREV STORY
FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

author_avatar
NASDAQ Market News

CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018

author_avatar
NASDAQ Market News

Immunoassay Market Worth $19.76 Billion by 2025, Growing at a CAGR of 5.9% from 2019 – Global Opportunity Analysis and Industry Forecasts by Meticulous Research®

author_avatar
NASDAQ Market News